EGFR mutant-specific inhibitor DZD6008

An orally available, blood-brain-barrier (BBB) penetrant, mutant-specific inhibitor of the receptor tyrosine kinase epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, EGFR inhibitor DZD6008 targets, binds to and inhibits certain EGFR mutations. This prevents EGFR-mediated signaling and may result in the inhibition of tumor growth in susceptible tumor cells. EGFR plays a major role in tumor cell proliferation and is often mutated in cancer cells.